by jmanor | May 16, 2022 | White Papers
There exists a large scientific literature on the value of improved health and how to incorporate that value into policy and decision making where activities impact health outcomes. The purpose of this policy brief is to review literature on the value of health in...
by susuguo | Apr 1, 2022 | White Papers
Almost exactly two years ago COVID-19 spread to the United States. Following the federalism model, the 50 states and their governors and legislators made many of their own pandemic policy choices to mitigate the damage from the virus. States learned from one another...
by susuguo | Feb 1, 2022 | White Papers
Marginal prices fell, and disposable incomes increased, for drug and alcohol consumers during the pandemic. Most of the amount, timing, and composition of the 240,000 deaths involving alcohol and drugs since early 2020 can be explained by income effects and...
by jmanor | Dec 15, 2021 | White Papers
This paper measures the impact of manufacturer-provided copay assistance on total out-of-pocket costs, drug utilization, and implications for patient outcomes. Using data dating back to 2015, we find manufacturer-provided copay assistance mitigated the rise in copay...
by jmanor | Dec 8, 2021 | White Papers
This paper revisits Peltzman (1973) in light of two recent opportunities to quantitatively assess tradeoffs in drug regulation. First, reduced regulatory barriers to drug manufacturing associated with the 2017 reauthorization of Generic Drug User Fee Amendments were...
by jmanor | Nov 30, 2021 | White Papers
This issue brief reviews the evidence-base to assess the impact of HR 5376 on drug innovation and patient health. A large academic literature estimates the effect of future drug revenues on R&D spending and finds that on average that a 1 percent reduction in...
